These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 12180038)

  • 1. [Clinical study of the month. Attempt at preservation of B cells during the initial phase of type 1 diabetes: negative results with ultralente insulin, but promising results with an anti-CD3 monoclonal antibody].
    Philips JC; Scheen AJ;
    Rev Med Liege; 2002 Jun; 57(6):413-7. PubMed ID: 12180038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Can we change the course of beta-cell destruction in type 1 diabetes?
    Gale EA
    N Engl J Med; 2002 May; 346(22):1740-2. PubMed ID: 12037155
    [No Abstract]   [Full Text] [Related]  

  • 3. Preservation of C-peptide secretion in subjects at high risk of developing type 1 diabetes mellitus--a new surrogate measure of non-progression?
    Schatz D; Cuthbertson D; Atkinson M; Salzler MC; Winter W; Muir A; Silverstein J; Cook R; Maclaren N; She JX; Greenbaum C; Krischer J
    Pediatr Diabetes; 2004 Jun; 5(2):72-9. PubMed ID: 15189492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes.
    Keymeulen B; Vandemeulebroucke E; Ziegler AG; Mathieu C; Kaufman L; Hale G; Gorus F; Goldman M; Walter M; Candon S; Schandene L; Crenier L; De Block C; Seigneurin JM; De Pauw P; Pierard D; Weets I; Rebello P; Bird P; Berrie E; Frewin M; Waldmann H; Bach JF; Pipeleers D; Chatenoud L
    N Engl J Med; 2005 Jun; 352(25):2598-608. PubMed ID: 15972866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lessons from type 1 diabetes for understanding natural history and prevention of autoimmune disease.
    Simmons K; Michels AW
    Rheum Dis Clin North Am; 2014 Nov; 40(4):797-811. PubMed ID: 25437293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Info-congress. Insulin therapy for preventing type 1 diabetes in high-risk relatives: negative results of the "Diabetes Prevention Trial-Type 1"].
    Scheen AJ; Philips JC
    Rev Med Liege; 2001 Jul; 56(7):536-8. PubMed ID: 11523307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Delay of type I diabetes in high risk, first degree relatives by parenteral antigen administration: the Schwabing Insulin Prophylaxis Pilot Trial.
    Füchtenbusch M; Rabl W; Grassl B; Bachmann W; Standl E; Ziegler AG
    Diabetologia; 1998 May; 41(5):536-41. PubMed ID: 9628270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Monoclonal antibodies in diabetes: almost approaching the dream?].
    Philips JC; Keymeulen B; Mathieu C; Scheen AJ
    Rev Med Liege; 2009; 64(5-6):327-33. PubMed ID: 19642469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New therapies aimed at the preservation or restoration of beta cell function in type 1 diabetes.
    Keymeulen B
    Acta Clin Belg; 2006; 61(5):275-85. PubMed ID: 17240745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Early diagnosis and prevention of type 1 diabetes: role of the Belgian Diabetes Registry].
    Weets I; Truyen I; Philips JC; Gorus F
    Rev Med Liege; 2005; 60(5-6):306-12. PubMed ID: 16035286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Otelixizumab: a novel agent for the prevention of type 1 diabetes mellitus.
    Miller SA; St Onge E
    Expert Opin Biol Ther; 2011 Nov; 11(11):1525-32. PubMed ID: 21913874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Type 1 diabetes--does suppressing T cells increase insulin?
    Lernmark A
    N Engl J Med; 2005 Jun; 352(25):2642-4. PubMed ID: 15972873
    [No Abstract]   [Full Text] [Related]  

  • 13. Exendin-4 improves reversal of diabetes in NOD mice treated with anti-CD3 monoclonal antibody by enhancing recovery of beta-cells.
    Sherry NA; Chen W; Kushner JA; Glandt M; Tang Q; Tsai S; Santamaria P; Bluestone JA; Brillantes AM; Herold KC
    Endocrinology; 2007 Nov; 148(11):5136-44. PubMed ID: 17673522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms mediating anti-CD3 antibody efficacy: insights from a mathematical model of type 1 diabetes.
    Young DL; Ramanujan S; Kreuwel HT; Whiting CC; Gadkar KG; Shoda LK
    Ann N Y Acad Sci; 2006 Oct; 1079():369-73. PubMed ID: 17130581
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Teplizumab for treatment of type 1 diabetes mellitus.
    Skelley JW; Elmore LK; Kyle JA
    Ann Pharmacother; 2012 Oct; 46(10):1405-12. PubMed ID: 22968521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-CD3 antibodies for type 1 diabetes: beyond expectations.
    Bach JF
    Lancet; 2011 Aug; 378(9790):459-60. PubMed ID: 21719098
    [No Abstract]   [Full Text] [Related]  

  • 17. Inhibition of autoimmune diabetes by oral administration of anti-CD3 monoclonal antibody.
    Ishikawa H; Ochi H; Chen ML; Frenkel D; Maron R; Weiner HL
    Diabetes; 2007 Aug; 56(8):2103-9. PubMed ID: 17456848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Prevention strategies of type 1 diabetes: the focus in 2003].
    Philips JC; Scheen AJ;
    Rev Med Liege; 2003 Apr; 58(4):211-9. PubMed ID: 12868323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-CD3 mAbs for treatment of type 1 diabetes.
    Kaufman A; Herold KC
    Diabetes Metab Res Rev; 2009 May; 25(4):302-6. PubMed ID: 19319985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [One step towards restoration of self-tolerance in human autoimmune diseases].
    Chatenoud L
    Med Sci (Paris); 2007 Feb; 23(2):167-71. PubMed ID: 17291426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.